[Effectiveness and tolerance of the C3 convertase inhibitor, N-acetyl-aspartyl-magnesium glutamate with anti-allergic action. Results of a double-blind study].
N-Acetyl-aspartyl magnesium glutamate (Rhinaaxia, NAAGA) is a topically active antiallergic dipeptide. The compound acts in two different ways. On the one hand NAAGA inhibits the mast cell-degranulation, on the other hand this compound blocks the activation of the C3-convertase, subsequently followed by a blocked cleavage of the fragments C3a and C5a, respectively. 20 patients suffering from pollinosis were treated for 2 weeks according to a randomized double-blind placebo-controlled study. Besides subjective complaints nasal obstruction was objectively documented via rhinomanometria. 9 out of 10 patients under placebo had to use the rescue drug tritoqualine, a histidine decarboxylase inhibitor, compared to none in the verum group (p less than 0.01). After 14 days of treatment with NAAGA the nasal peak flow rate increased by 21.5 l/min and 21.8 l/min in the tritoqualine/placebo group, respectively (not significant). Nasal obstruction improved statistically significantly after 7 and 14 days of treatment in both groups. Tolerance was reported to be good in either group.
Gastpar
H
H
Universitäts-HNO-Klinik, München.
Kiehn
R
R
Sieger
C
C
Weibel
M A
MA
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003166:Complement Activating Enzymes / Q000037:antagonists & inhibitors*; D050577:Complement C3-C5 Convertases / Q000037:antagonists & inhibitors*; D004151:Dipeptides / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D008297:Male; D008365:Manometry; D009297:Nasal Mucosa / Q000503:physiopathology; D011897:Random Allocation
D004151:Dipeptides; C027172:isospaglumic acid; D003166:Complement Activating Enzymes; D050577:Complement C3-C5 Convertases
Wirksamkeit und Verträglichkeit des C3-Konvertasehemmers N-Acetyl-Aspartyl-Magnesiumglutamat mit antiallergischer Wirkung. Ergebnisse einer doppelblinden Phase-II-Studie.